Celsion denies plans to sell BPH (benign prostatic hyperplasia) business
This article was originally published in Clinica
Executive Summary
Celsion, formerly Cheung Laboratories, says it has no intention of selling its benign prostatic hyperplasia (BPH) business "at this time". The announcement was made in response to an unsolicited offer, which the Celsion management found "did not reflect a true and fair value" of the business.